Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,

Abstract

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,

Abstract

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,

Abstract

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

Org: Netherlands Cancer Institute, Henry Dunant Hospital, Universitätsspital Zürich, University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre,

Abstract

ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.

Org: University College London Hospital NHS Trust and Great Ormond Street Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), IRCCS Istituto Ortopedico Rizzoli, Hospital Universitario Miguel Servet,

Abstract

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Org: Memorial Sloan Kettering Cancer Center, Duke University Medical Center, Vall d’Hebron University Hospital/VHIO, Institut Català d'Oncologia L´Hospitalet, Ramón y Cajal University Hospital,

Abstract

Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.

Org: Sarah Cannon Research Institute/Tennessee Oncology, Asan Medical Center, Samsung Medical Center, Menarini Group, Hospital Universitario 12 de Octubre,

Abstract

Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,

Abstract

Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.

Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,

Abstract

IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).

Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,

Abstract

Meta-analysis of perioperative immune checkpoint inhibitors in urothelial and renal cell carcinoma: Data from the latest available evidence.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Madrid, Spain, Medical Oncology Service, 12 de Octubre University Hospital,

Abstract

SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.

Org: University of Sheffield, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy Département d'Organisation du Parcours Patient, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,

Abstract

Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.

Org: Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid (UCM), Virgen del Rocío University Hospital, Hospital Universitario Vall d'Hebron, Hospital Universitario Virgen del Rocio,

Clinical trial

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial

Status: Active (not recruiting), Estimated PCD: 2025-01-31

Clinical trial

Prospective Multicentre Observational Study of Patients Treated With Vasopressin in Critical Care Units

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction (COLIGROW)

Status: Recruiting, Estimated PCD: 2025-05-27

Abstract

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Org: Erasmus MC Cancer Center, Rotterdam, Netherlands Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Fondazione IRCCS Istituto Neurologico Carlo Besta,

Abstract

Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.

Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,

Abstract

New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).

Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,

Abstract

Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.

Org: Gustave Roussy Département d'Organisation du Parcours Patient, Chris O'Brien Lifehouse, Washington University Medical School, Hospital Universitario 12 de Octubre, University of Pittsburgh School of Medicine,

Abstract

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

Org: University of Texas MD Anderson Cancer Center, Veneto Institute of Oncology IOV - IRCCS, Hospital Universitario 12 de Octubre, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.

Abstract

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.

Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,

Abstract

SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Central University Hospital of Asturias, Hospital Juan Ramón Jiménez de Huelva, Hospital Clínic de Barcelona, IDIBAPS,

Abstract

Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).

Org: Tom Baker Cancer Centre, University of Calgary, BC Cancer Agency Vancouver Island Centre, University Hospital of Southern Denmark, University of Bari 'A. Moro',

Abstract

Proactive assessment of patient reported outcomes in patients with ovarian cancer.

Org: 12 de Octubre University Hospital, Wollongong Hospital, Princess Margaret - University Health Network, Hospital Universitario 12 de Octubre, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,

Abstract

Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.

Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,

Abstract

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.

Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,

Abstract

Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.

Org: Sylvester Cancer Center, Emory University School of Medicine, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Hospital Germans Trias i Pujol, Institut Català D'Oncologia,

Abstract

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

Org: Sorbonne University and Saint-Antoine Hospital, Hôpital Saint-Antoine, INSERM UMRs938, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,

Abstract

A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).

Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,

Abstract

Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.

Org: Institut Curie, Saint Cloud, France, University of Paris-Saclay, Hôpital Pour Enfants De La Timone, Hospital Universitario 12 de Octubre, Hospital U i P La Fe,

Abstract

Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Org: Hospital Universitario 12 de Octubre, Hospital Teresa Herrera-Materno Infantil, Complejo Hospitalario Universitario A Coruna, Hospital Universitario Regional Málaga, Fundacion Jimenez Diaz University Hospital,

Abstract

Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).

Org: Targovax ASA, Hospital Universitari Vall d´Hebron and Vall d´Hebron Institute of Oncology (VHIO), CHU Rennes – Hôpital Pontchaillou, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit,

Abstract

The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).

Org: Medical Oncology Group, Hospital Universitario Ramón y Cajal, MD Anderson Cancer Center, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University Hospital Virgen del Rocío,

Abstract

Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in high risk non–muscle- invasive bladder cancer (NMIBC) patients: Safety interim report of BladderGATE phase I-II study.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Unidad de Oncología Molecular CIEMAT, Unidad de Oncologia Molecular CIEMAT, Urology Department,

Clinical trial

The Effect of Heliox on the Work of Breathing in Adult Patients With Lower Airway Stenosis

Status: Active (not recruiting), Estimated PCD: 2023-05-31

Abstract

ASSOCIATION BETWEEN DISEASE ACTIVITY AND DAMAGE IN IDIOPATHIC INFLAMMATORY MYOPATHIES. DIFFERENCES BETWEEN INCIDENT AND PREVALENT CASES

Org: Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain, Hospital del Mar, Barcelona, Spain,